Quick Answer
STANDARD BIOTOOLS INC. reported Gross Profit of $42.54 million for the year ending 2025.
- STANDARD BIOTOOLS INC. showed a decrease of -5.2% in Gross Profit from 2024 to 2025.
- This data is from STANDARD BIOTOOLS INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $13.43 million | Q2 2018: $13.59 million | Q3 2018: $15.82 million | Q1 2019: $16.99 million | Q2 2019: $15.36 million | Q3 2019: $14.04 million | Q2 2022: $4.43 million | Q3 2022: $9.22 million | Q1 2023: $12.28 million | Q2 2023: $13.60 million | Q3 2023: $11.15 million | Q1 2024: $24.19 million | Q2 2024: $10.37 million | Q3 2024: $12.13 million | Q1 2025: $19.74 million | Q2 2025: $10.63 million | Q3 2025: $9.48 million.
- Over the full 8 years of available data (2016 to 2025), STANDARD BIOTOOLS INC.'s Gross Profit has declined by 27.2%.
- Historical annual values: Fiscal year 2025: $42.54 million | Fiscal year 2024: $44.88 million | Fiscal year 2023: $50.45 million | Fiscal year 2022: $37.05 million | Fiscal year 2019: $64.28 million | Fiscal year 2018: $61.65 million | Fiscal year 2017: $51.98 million | Fiscal year 2016: $58.44 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: